EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access

Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial

Carlos M Grilo iD, Janet A Lydecker iD, Ania M Jastreboff iD, Brian Pittman, Sherry A McKee

Obesity · 2023

DOI: 10.1002/oby.23898 ↗

At a glance

Randomisierte kontrollierte Studie in Obesity, 2023. Written by Carlos M Grilo and 4 co-authors. Institution: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA. Major MEDLINE topics: Binge-Eating Disorder, Bulimia. Cited 39 times so far (Crossref); 45 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NCATS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Binge‐eating disorder (BED) is a prevalent psychiatric disorder associated with obesity. Few evidence‐based treatments exist for BED, particularly pharmacological options. This study tested the efficacy of naltrexone/bupropion for BED.

Methods

A randomized, double‐blind, placebo‐controlled, 12‐week trial tested naltrexone/bupropion for BED with and without obesity. Eighty‐nine patients (70.8% women, 69.7% White, mean age 45.7 y, mean BMI 35.1 kg/m 2 , 77.5% with BMI ≥ 30 kg/m 2 ) were randomized to placebo ( n = 46) or naltrexone/bupropion ( n = 43), with randomization stratified by obesity status and gender; 92.1% completed post‐treatment assessments.

Results

Mixed models of binge‐eating frequency revealed significant reductions that did not differ significantly between naltrexone/bupropion and placebo. Logistic regression of binge‐eating remission rates revealed that naltrexone/bupropion and placebo did not differ significantly. Obesity status did not predict, or moderate, binge‐eating outcomes considered either continuously or categorically. Mixed models revealed that naltrexone/bupropion was associated with significantly greater percentage weight loss than placebo. Logistic regression revealed that naltrexone/bupropion had significantly higher rates of attaining ≥5% weight loss than placebo (27.9% vs. 6.5%). Obesity status did not predict or moderate weight‐loss outcomes.

Conclusions

Naltrexone/bupropion did not demonstrate effectiveness for reducing binge eating relative to placebo but showed effectiveness for weight reduction in patients with BED. Obesity status did not predict or moderate medication outcomes.

Subjects

MeSH terms (MEDLINE)

Binge-Eating DisorderBulimiaHumansFemaleMiddle AgedMaleBupropionNaltrexoneObesityWeight LossDouble-Blind MethodTreatment Outcome

Substances

BupropionNaltrexone

Authors and institutions

  • Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Department of Medicine (Endocrinology and Metabolism), Yale University School of Medicine, New Haven, Connecticut, USA.

ORCID profiles: Carlos M Grilo, Janet A Lydecker, Ania M Jastreboff

Funding

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Grilo, C. M., Lydecker, J. A., Jastreboff, A. M., Pittman, B., & McKee, S. A. (2023). Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity. https://doi.org/10.1002/oby.23898

Vancouver

Grilo CM, Lydecker JA, Jastreboff AM, Pittman B, McKee SA. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity. 2023. doi:10.1002/oby.23898

BibTeX
@article{Grilo2023,
  author = {Grilo, Carlos M and Lydecker, Janet A and Jastreboff, Ania M and Pittman, Brian and McKee, Sherry A},
  title = {Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial},
  journal = {Obesity},
  year = {2023},
  doi = {10.1002/oby.23898}
}
Start for free →